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Abstract
Open collaboration and sharing of information among scientists at scientific meetings can foster innovation and 
discovery. However, such sharing can be at odds with potential patenting and commercialization objectives. This 
tension may be mitigated if certain procedures are followed in the context of scientific meetings. The article first 
discusses what makes a scientific finding patentable and then sets out four specific patent issues for scientists to 
consider before attending a scientific meeting and sharing their research. Finally, it provides recommendations on how 
scientists can best protect their intellectual property rights while sharing information at scientific meetings.
Review
Scientific communities thrive on collaboration, which
requires sharing information. Once discovered and dis-
closed, however, valuable information is forever in the
public domain. Information is thus the classic example of
a public good: once made available information can be
possessed by any number of individuals at once, and
becomes impossible to control [1]. Without some form of
reward, there may be insufficient incentive to encourage
investments that yield socially valuable information [2].
One way by which society rewards socially useful inge-
nuity is through patents, which are exclusive rights to the
use of an invention. Exclusivity protection for inventions
has been recognized for centuries [3], and a corporation's
patent portfolio may be its most valuable asset. Academic
institutions have also come to increasingly value and
apply for patents.
At the intersection of academia and the patent system is
an inevitable tension between the imperative of informa-
tion dissemination and the pursuit of profit [4]. This ten-
sion is, in part, a direct consequence of a universal
requirement for patent protection - namely, that a patent
will not issue, or will be declared invalid, if the claimed
invention was previously disclosed to the public. The risk
of forfeiting rights to a patent through careless disclosure
can lead scientists to purposely hide their discoveries to
preserve their economic rights. One study, by Grushcow,
found that scientists who eventually patent their work
appear to withhold presentation of their data at scientific
conferences for periods of months, or even years, and
that academic and nationally funded scientists who were
not seeking a patent presented their abstracts over a year
earlier than scientists who were seeking patents [5].
Another study found that secrecy is on the rise among
academic researchers (particularly those in the life sci-
ences), due to a desire to participate in patenting and
technology transfer [6].
The relationship between patent protection and disclo-
sure of research findings is complex, and in some circum-
stances, patents may speed disclosure. For example, the
patent system does promote eventual disclosure soon
after a patent is filed, whereas the absence of adequate
patent protection could promote long-term secrecy of
inventions so that they may be protected as trade secrets
[7]. Further, where multiple parties are racing for patent
protection, the lagging party may choose to publish their
findings prematurely to limit the availability of a patent
for the leading party [8].
Nevertheless, the overarching tension between protec-
tion and dissemination of research findings may affect
global scientific collaborations, even those with a human-
itarian objective like the "Grand Challenges in Global
Health" initiative. Each year, 44 research teams with
members from 33 countries assemble to discuss their
findings. At one of these meetings, a scientist declined to
provide specific details about the findings of a particular
aspect of his research. The reason given was a concern
about prematurely disclosing information that could
threaten the granting of a patent.
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Much discussion and debate ensued among the meet-
ing participants as to the validity of the scientist's deci-
sion not to disclose. Was the scientist undermining the
collaborative nature of the initiative? Or was his position
a prudent one that would be more likely to ensure the dis-
covery reached those who needed it in the developing
world? While previous articles have examined academia-
industry patenting with respect to publications and con-
ferences [1,6,9-11] there has been little explication of how
these factors influence scientific collaboration and collab-
orative scientific meetings. The purpose of this article
therefore is to provide researchers and research funders
with analysis and recommendations of patenting issues
related to scientific collaboration and meetings.
What Makes a Scientific Finding Patentable?
Patentability is not typically a function of how much work
is done to arrive at a result; rather, it lies in the unexpect-
edness or difficulty of an invention and the reduction of
that invention to a commercially useful result [12]. There
are three basic requirements for patentability of an inven-
tion: novelty, non-obviousness, and utility (see Appendix
1) [13-15]. Novelty pertains to the timeliness of the dis-
closure of the scientific finding. A patent may be available
only as long as there is no "prior art" (document, product,
presentation, etc.) that has already disclosed each ele-
ment of the invention [16].
Non-obviousness, or the requirement of an "inventive
step", imposes a threshold of ingenuity to the scientific
finding. Even if the subject matter has never been publicly
disclosed, if it would be obvious for an ordinary person
skilled in the relevant field based on the literature and
common body of knowledge in that field, then the subject
matter is not deserving of a patent [17-19].
Utility means the invention disclosed in the patent
must 'work'. Society will not reward a useless finding,
even if it is new and not obvious. For example, a new drug
delivery system that fails to make an active ingredient
available in the body does not attract a patent. Only once
someone finds a use for the drug delivery system might a
patent be available.
Finally, some subject matter may not be patentable,
such as scientific principles and abstract theorems - e.g.,
the laws of physics. In some places, methods of medical
treatment - such as surgical methods or dosage regimens
- are not patentable. Genetically-modified living beings,
genes in isolation, or even an oncogenic mouse are pat-
entable in some jurisdictions, and to varying extents [20].
Attending a Scientific Meeting? Specific Patent 
Issues to Consider
1. Timing of Disclosure
Ordinarily, in considering whether to patent, inventors
will want protection in at least two markets - the United
States and Europe - and then often Japan also. The desire
for protection elsewhere will depend on the commercial
strategy of the inventor or their financial sponsor. Before
disclosing their invention, a potential patent applicant
should consult with a patent attorney to craft a patent
strategy and learn what conduct could jeopardize that
strategy in their markets of interest. For inventors at aca-
demic institutions, this service may be available through a
university technology transfer office.
The patent system in some jurisdictions affords leeway
to patentees to disclose their scientific findings before
applying for a patent. However, that leeway is neither uni-
versal nor everlasting. In the United States, inventors
have one year from the time they first disclose their scien-
tific findings to apply for a patent for their work. This
one-year grace period is helpful, and promotes disclosure
to some extent, but can be risky. Only disclosure made by
the inventor - not necessarily members of their team -
during this one year is immunized. Furthermore, in
Europe, the inventor does not benefit from any such
grace period so if patent protection is sought in Europe,
secrecy as to the content of the invention is essential until
the European patent application has been filed.
2. Extent of Disclosure
The amount of information that a scientist discloses pub-
licly has implications on the patentability of her findings,
as well as those of other scientists in the field.
The potential risks associated with disclosure in a con-
fidential setting will vary according to the ease of the
invention's replication. Some inventions are easily repli-
cable once disclosed - such as the identification of a key
receptor in the body. Other inventions may only be repli-
ca t ed  o v e r  s ev e r a l  y e a r s  -  s u c h  as  t h e  f i n d i n g s  f r o m  a
long-term study carried out in monkeys. In determining
whether to disclose findings in a scientific meeting,
researchers should assess how realistic it is for a competi-
tor to copy the disclosed findings before the researcher is
able to file for patent protection.
In the US, to offset the risk of getting "scooped" by
rivals, inventors can file provisional patent applications
that act as placeholders for a more careful definition of
the property claimed by the inventors. This affords the
inventor latitude in disclosing such findings in other
forums.
Once a patent application has been filed, the calculus
governing the extent of disclosure changes. Whereas dis-
closure prior to a patent application risks undermining an
eventual patent, disclosure after the application is filed
will not compromise that application. On the contrary,
extensive disclosure after filing a patent application may
bar future patent applications in the field - both by the
discloser and by competitors. Therefore, after a patent
application is filed, the commercial interests of the inven-Lipkus et al. Health Research Policy and Systems 2010, 8:15
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tor may align with the scientist's interests in disclosure -
say as much as possible about the research findings, not
only to advance academic discourse but also to thwart
competitive patenting opportunities.
3. The Audience
Whether any given disclosure has been made "public" is a
matter of evidence and depends on the circumstances of
the disclosure. A document published in a peer-reviewed
journal commonly circulated within the relevant commu-
nity is of course public, but other disclosures may not be.
A fundamental aspect of patent law is that an invention
is not novel if it has ever been disclosed in the past (with
some exceptions which are beyond the scope of this
paper) [21,22]. Therefore, even an article in an obscure
journal would appear to preclude subsequent patentabil-
ity , as long as it taught each of the key features of the
invention and contains enough information to enable a
fellow scientist to practice the invention. Where a past
article does not contain the entirety of the invention, a
patent for the invention may only be invalidated on the
basis of the obviousness doctrine.
A poster presentation or casual conversation raises the
question of oral disclosures. For US patentability pur-
poses, only an oral disclosure that takes place in the US
will factor into the patentability decision for a US patent.
This is a particularly important consideration for groups
of international scientists who could choose to have
meetings outside of the US. For Europe, however, an oral
disclosure anywhere in the world is considered.
If there is a duty of confidentiality between the parties
or if a contract existed either written or oral stipulating
that the findings would be kept confidential, the disclo-
sure may legally be considered a trade secret and there-
fore not qualify as publication. In a controlled setting, a
non-disclosure agreement can be a productive way of
sharing information without causing that information to
be deemed "public" for the purposes of patentability. Such
an agreement would set out the designation of the shared
information as secret and the obligation of the recipient
to keep the information secret. One caveat, though, is
that if a counterparty to a non-disclosure agreement dis-
closes the invention in violation of the agreement before
the inventor has filed for patent protection, patentability
may be lost [23]. The only remedy will be a damages
claim for breach of the confidentiality agreement.
In practice, even the most sophisticated companies
often rely on non-disclosure agreements to explore the
commercial viability of their inventions even before
applying for patents. This is normally seen as a safe way
for companies to capitalize on their inventions where
they are unable to fully develop their inventions alone.
Most companies fortunate enough to be confidentially
exposed to new technologies will respect the confidential
arrangement in order to demonstrate their reputation for
being respectful of rights among companies in their
industry.
In the scientific meeting context, a non-disclosure
agreement could have a similar disciplining effect among
researchers as it does among companies in large indus-
tries. Scientists seen as "scooping" inventions of other
attendees in violation of non-disclosure agreements
would develop poor reputations among all attendees of a
meeting, and would consequently be seen as untrust-
worthy within the academy. Non-disclosure may there-
fore provide the appropriate degree of discipline at the
outset of scientific meetings to ensure mutual respect for
the rights of researchers at the meeting.
Finally, the circumstances of any disclosure are impor-
tant. If two researchers are employees of a larger organi-
zation, they may be free to share their findings within the
organization only. On the other hand, disclosure during a
conversation between representatives of two market
competitors may well lead to the disclosure being used
against the patent applicant should its competitor seek to
undermine the patent. Less clear is the situation where
findings are disclosed between two members of a scien-
tific team, funded by the same grant but in different uni-
versities. As mentioned above, a well-drafted non-
disclosure agreement may render the contents of either of
the latter two conversations non-public.
4. The Irrelevance of Why
The social importance of an invention neither renders it
more or less patentable, for the most part. The patent sys-
tem is completely agnostic to the field of the invention or
its potential social benefit - the same rules apply to AIDS
medicines as to gardening equipment.
There is one caveat, however, of particular relevance for
doctors. As a matter of public policy, some countries have
refused to permit patents for subject matter normally
within the realm of the professional skill of doctors.
These "methods of medical treatment" may include such
things as surgical techniques and dosage regimens. The
World Trade Organization has permitted countries to
provide exceptions to patentability for such subject mat-
ter; Europe and Canada have availed themselves of such
an exception, and the United States has not.
The overall inflexibility of the patent system to adapt to
different contexts places the onus on scientific communi-
ties to adapt to the realities brought about by patents.
Collaboration between the public and private sectors and
interests is critical to optimizing information-sharing
among those with the power to solve difficult problems.
For example, the Bill & Melinda Gates Foundation
developed a Global Access Strategy for its grants, which
aims to ensure that any global health solutions that arise
from the funded projects will be made accessible to peo-Lipkus et al. Health Research Policy and Systems 2010, 8:15
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ple most in need within developing countries and that
knowledge gained through discovery is promptly and
broadly made available to the scientific community. Sci-
entists are required to describe how potentially patent-
able information will be handled. While the scientist (or
their institution) retains the intellectual property, many
of the agreements used in the initiative provide 'march in
rights' to a non-profit or academic institution if the com-
m e r c i a l i z i n g  p a r t y  f a i l s  t o  l i v e  u p  t o  t h e  g l o b a l  a c c e s s
commitments. This approach is an example of how orga-
nizations and scientists can establish guidelines to pro-
mote dissemination and sharing of information while still
recognizing the realities of the patent system and related
commercial objectives.
Guidance for Researchers and Funders
We offer ten suggestions for retaining patent rights with-
out unnecessarily withholding information in scientific
meetings (see Appendix 2):
Before the Meeting
1. Clarify who owns the intellectual property flowing from 
collaborative research
The reality of today's research collaboration is that results
from research funded by private interests often do make
their way into scientific meetings. Participants should not
be made to guess as to who will own the rights flowing
from their work. A clear ownership policy from the start
on the part of the funding organization (or organizations)
is essential [24].
2. Use non-disclosure agreements in scientific meetings but 
only as needed
Participants can contractually bind themselves to keep
the research findings of fellow researchers confidential.
Any agreements should cover only those meetings where
sensitive information is being exchanged and a level of
protection is required. It must be recognized, though,
that confidentiality agreements can chill valuable collabo-
ration by silencing contracting parties, and so they should
not be overused or made too onerous. In most cases, it
would be overbroad to include traditionally public meet-
ings, such as annual meetings of not-for-profit organiza-
tions, within the scope of a confidentiality agreement.
Penalties for breaching confidentiality agreements should
be no more than is necessary to adequately deter disclo-
sure.
3. Consider holding meetings outside of the US due to US 
patent law
Currently, only oral disclosures made in the US are taken
into consideration in evaluating US patentability. Unless
and until this situation changes, oral disclosures at for-
eign meetings should not forfeit US patent rights. Be cau-
tious when relying on this strategy, as it is specific to the
US, and US law could change.
At the Meeting
4. Be wary of meetings that include all experts in a field
Efforts to maintain confidentiality with a non-disclosure
agreement or other agreement may be pointless if all the
members of a field are present. The information may no
longer be considered a secret and it is possible that a
court would consider disclosure in such consequences to
be a public disclosure that invalidates a later-filed patent.
5. Do not publish detailed meeting minutes
If contents of a meeting are written down and published,
that disclosure will count against the discloser by patent
offices examining the novelty of the discloser's subse-
quent patent application. The less detailed the meeting
minutes, the less likely such minutes will contain a
detailed enough description of the findings to undermine
patentability.
6. Provide a schedule for eventual disclosure if disclosure at 
a meeting is not possible
Delays in filing for patent protection are often not the
fault of the researcher, and researchers should - as a cour-
tesy to fellow collaborators - ensure that if they are unable
to share information on a particular meeting date, that
they can provide some indication of when disclosure will
be made available. Since disclosure will presumably be
extensive within the patent application's specification,
circulation of the patent application itself to fellow
researchers on a date committed to in advance (under a
non-disclosure agreement, if desired) can alleviate a past
refusal to disclose for patentability purposes.
7. Talk to a patent attorney, or a technology transfer office
An independent attorney with knowledge of the patent
system can help an inventor understand the implications
of disclosure in the context of his own invention. Where
available, technology transfer offices at universities can
also act as a bridge between the inventor and the patent
system, and even participate in the funding of the inven-
tion's commercialization.
8. Consider filing early for patent protection
Early patent filing can provide tremendous benefits. First,
once an application has been filed, the content of subse-
quent disclosures will not forfeit patent rights. Second, if
other researchers are working toward similar solutions,
filing a patent application secures first-in-time rights to
the invention for the applicant. In countries other than
the United States, this early filing is dispositive of any dis-
pute over ownership. In the US, it minimizes the costs
associated with obtaining a patent at the end of the day,Lipkus et al. Health Research Policy and Systems 2010, 8:15
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since less earlier-published literature will be available to
interfere with the patent application.
9. Before filing a patent application, be cautious in 
disclosing research results
Absent a non-disclosure agreement in a scientific meet-
ing, disclosure should be confined to information already
in the public domain. Scientists may also disclose the
problem they are interested in solving, however even that
disclosure may evidence a motivation to solve a problem
in a certain way. If patent protection is desired, scientists
should be mindful that disclosure of findings before filing
may compromise patentability. An early patent filing pol-
icy can render this concern moot.
10. After filing a patent application, consider disclosing 
extensively as part of a collaboration-friendly commercial 
strategy
Once the patent application has been filed, there may be
no further interest in keeping research findings secret. In
fact, more extensive disclosure of research findings can
sometimes bolster a researcher's commercial interests.
Broad disclosure can forestall competitors by creating a
commons of information even broader than the boundar-
ies of the patent. This makes it much harder for others to
patent inventions in the area, and allows society to bene-
fit from the follow-on research deriving from the inven-
tion without paying monopoly prices. However, where
the inventor is considering further incremental inven-
tions in the field, extensive disclosure could make patent-
ing such potential inventions more difficult.
Conclusions
This article has attempted to provide background infor-
mation to assist researchers in understanding what pat-
ents are about, while also offering strategies for
reconciling competing interests in collaborative scientific
meetings.
This article was intended to provide guidance within
the context of existing patent laws. However, legislative
reform creating exemptions for oral disclosures or insti-
tuting grace periods for certain socially-beneficial oral
disclosures are avenues that would reduce the risks of dis-
closure for scientists and funders. For example, Grush-
cow suggests amending the US Patent Act to specifically
allow for early data sharing at academic conferences
without threatening patentability [5]. Bagley suggests cre-
ating an opt-in system in the US where academic
researchers could choose to have two years instead of one
to disclose the invention before filing a patent application
[6]. Grushcow and Bagley, however, recognize that such
amendments have their failings. These amendments
would not protect a scientist from the laws in other coun-
tries (unless harmonization occurs), they will not assist
industry sponsored research, and they appear to contra-
dict the policy behind the disclosure rule - i.e. a reluc-
tance to allow inventions already in the public domain to
be reclaimed by the inventor [5].
Until such changes to the patent laws are adopted the
recommendations provided above should help guide dis-
cussions between researchers and funders. It is our hope
that these guidelines can help calibrate disclosure poli-
cies, agreements and perhaps eventually a model declara-
tion so that academic and commercial interests are
preserved in the context of vital collaborative research.
Appendix 1: What makes a Scientific Finding 
Patentable?
1. Is the invention new?
2. Is the invention novel or non-obvious?
3. Will the invention work, as described?
4. Is the subject matter patentable?
Appendix 2: How to best protect your intellectual 
property rights while sharing results at scientific 
meetings
Before the Meeting
1. Clarify who owns the IP flowing from collaborative
research.
2. Use balanced non-disclosure agreements in scien-
tific meetings but only as needed.
3. Consider holding meetings outside of the US due to
US patent law.
At the Meeting
4. Be wary of meetings that include all experts in field.
5. Do not publish detailed meeting minutes.
6. Provide a schedule for eventual disclosure, if disclo-
sure at a meeting is not possible.
Timing Your Disclosures
7. Talk to a patent attorney, or a technology transfer
office.
8. Consider filing early for patent protection.
9. Before filing a patent application, be cautious in
disclosing results.
10. After filing a patent application, consider disclos-
ing extensively as part of a collaboration-friendly
commercialization strategy.
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